https://www.selleckchem.com/pr....oducts/kd025-(slx-21
rmacoepidemiological studies evaluating utilization, effectiveness, and safety of medication use, which would facilitate evidence-based treatment decision-making.Rearranged during transfection (RET) rearrangements occur in 1% to 2% of lung adenocarcinomas as well as other malignancies and are now established targets for tyrosine kinase inhibitors. We developed three novel RET fusion-positive (RET+) patient-derived cancer cell lines, CUTO22 [kinesin 5B (KIF5-RET fusion], CUTO32 (KIF5B-RET fusion), and CUTO42 (echinoderm microt
Like
Comment
Share
